# OnCo record nct04849364 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04849364/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04849364", "NCT04849364" ;
  schema:name "PERSEVERE: genomically directed post-neoadjuvant residual TNBC"@en ;
  schema:description "This study assigned extra treatment after surgery using blood and tumour tests. It stopped and is no longer an access route."@en ;
  schema:url <https://onco.cc/trials/nct04849364/> ;
  schema:dateModified "2026-10-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04849364> ;
  onco:status "withdrawn" ;
  onco:phase "2" ;
  schema:startDate "2021-08-24" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/pembrolizumab/> .